๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› IgA Nephropathy (IgAN)
Clinical trial register · China

IgA Nephropathy (IgAN) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Shanghai 4 Hangzhou 4 Chengdu 2 Guangzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Shanghai4 Hangzhou4 Chengdu2 Guangzhou2
All 20 locations
Target enrolment
to

IgA Nephropathy (IgAN) trials in China

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
NCT07389499IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy
Grit Biotechnology
Phase EARLY_PHASE1
30
Shanghai
2027-08
Not yet open
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
NCT07746453IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Guangdong Provincial People's Hospital
Not applicable
24
Guangdong
2026-08-31
Recruiting
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
NCT07822100IgA Nephropathy (IgAN), Henoch Schรถnlein Purpura Nephritis
Hong Zhang
Not applicable
374
Beijing
2026-08-24
Recruiting
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
NCT07604311IgA Nephropathy (IgAN)
Nanfang Hospital, Southern Medical University
Phase 4
288
Guangzhou
2026-06-23
Not yet open
SLN12140 in Adult Participants With IgA Nephropathy in China
NCT07553494IgA Nephropathy (IgAN)
Linno Pharmaceuticals, Inc.
Phase 2
48
Beijing
2026-05-29
Recruiting
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
NCT07614477Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
Everest Medicines (China) Co.,Ltd.
Phase 2
45
Beijing, Tianjin
2026-05-20
Recruiting
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
NCT07586267Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1
15
Hangzhou
2026-05-08
Not yet open
Efficacy and Safety of CD19 CAR-ฮณฮด T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
NCT07535138Membranous Nephropathy, Lupus Nephritis (LN), IgA Nephropathy (IgAN)
Air Force Military Medical University, China
Phase EARLY_PHASE1
15
Xi'an
2026-05-01
Recruiting
Phase โ…ข Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
NCT07507201Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
The Children's Hospital of Zhejiang University School of Medicine
Phase EARLY_PHASE1
15
Hangzhou
2026-04-01
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
15
Hangzhou
2025-12-01
Recruiting
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
NCT07305974IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Phase 2
30
Beijing
2025-09-08
Recruiting
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
NCT07616700IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
73
Beijing
2025-08-25
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
NCT06819826IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.
Phase 3
360
Guangzhou
2025-02-14
Not yet open
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
NCT06687174IgA Nephropathy (IgAN)
Wuhan Createrna Science and Technology Co., Ltd
Phase 2
72
Beijing
2024-12-31
Recruiting
Efficacy and Safety of Telitacicept in IgAN
NCT06654596IgA Nephropathy (IgAN), Kidney Diseases, Telitacicept, Glucocorticoid
Ruijin Hospital
Not applicable
118
Shanghai
2024-12-06
Recruiting
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
NCT06676007IgA Nephropathy (IgAN), Early Initial Therapy
Sichuan Provincial People's Hospital
Observational
200
Chengdu
2024-10-30
Active, closed
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
NCT07098897IgA Nephropathy (IgAN)
The Affiliated Hospital of Xuzhou Medical University
Phase 3
150
Xuzhou
2024-08-01
Recruiting
Raman Spectroscopy Diagnosis of Kidney Diseases
NCT06760845IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
Zunsong Wang
Observational
200
Jinan
2021-02-01
Active, closed
Model Development and Application Based on Renal Pathology Images
NCT07816874Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
8,000
Wuhan
2019-01-01
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/iga-nephropathy-igan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition IgA Nephropathy (IgAN).

How many IgA Nephropathy (IgAN) trials are recruiting in China?

13 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (IgA Nephropathy (IgAN)), 21 studies
PhaseStudiesRecruitingShare
Phase 26328.6%
Phase EARLY_PHASE14219%
Not applicable3214.3%
Observational3214.3%
Phase 33214.3%
Phase 1114.8%
Phase 4114.8%

Most active sponsors

Lead sponsors with the most studies (IgA Nephropathy (IgAN))
Lead sponsorStudiesRecruiting
The Children's Hospital of Zhejiang University School of Medicine33
Haisco Pharmaceutical Group Co., Ltd.22
Air Force Military Medical University, China10
Biocity Biopharmaceutics Co., Ltd.11
Everest Medicines (China) Co.,Ltd.11
Grit Biotechnology10
Guangdong Provincial People's Hospital10
Hong Zhang11
Linno Pharmaceuticals, Inc.10
Nanfang Hospital, Southern Medical University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.